Sarcoma Therapeutics
1. Gleevec patent expiration
Treatment: A method for treating a tumor disease; Gleevec is also indicated for the treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (gist)
GLEEVEC IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE43932 | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jul, 2018
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5521184 (Pediatric) | NOVARTIS | Pyrimidine derivatives and processes for the preparation thereof |
Jul, 2015
(10 years ago) | |
| US6894051 | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
May, 2019
(6 years ago) | |
| US5521184 | NOVARTIS | Pyrimidine derivatives and processes for the preparation thereof |
Jan, 2015
(11 years ago) | |
| USRE43932 | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jan, 2019
(6 years ago) | |
| US6958335 | NOVARTIS | Treatment of gastrointestinal stromal tumors |
Dec, 2021
(4 years ago) | |
| US7544799 | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jan, 2019
(6 years ago) | |
|
US7544799 (Pediatric) | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jul, 2019
(6 years ago) | |
|
USRE43932 (Pediatric) | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jul, 2019
(6 years ago) | |
|
US6894051 (Pediatric) | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Nov, 2019
(6 years ago) | |
|
US6958335 (Pediatric) | NOVARTIS | Treatment of gastrointestinal stromal tumors |
Jun, 2022
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-583) | Dec 19, 2011 |
| Orphan Drug Exclusivity(ODE) | Jan 25, 2020 |
| New Indication(I-666) | Jan 25, 2016 |
| Orphan Drug Exclusivity(ODE-40) | Jan 25, 2020 |
Drugs and Companies using IMATINIB MESYLATE ingredient
Market Authorisation Date: 10 May, 2001
Dosage: CAPSULE; TABLET
How can I launch a generic of GLEEVEC before it's drug patent expiration?
More Information on Dosage
GLEEVEC family patents
2. Tazverik patent expiration
Treatment: Method of treating a lung metastasis of epithelioid sarcoma; Method of treating relapsed or refractory follicular lymphoma; Method of treati...
TAZVERIK's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9394283 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(7 years from now) | |
| US11052093 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US9090562 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US12168015 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US8410088 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Jan, 2034
(8 years from now) | |
| US10821113 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9872862 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(7 years from now) | |
| US9522152 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(6 years from now) | |
| US9889138 | EPIZYME INC | Method for treating cancer |
Oct, 2035
(9 years from now) | |
| US8765732 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US9549931 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US9334527 | EPIZYME INC | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(5 years from now) | |
| US9333217 | EPIZYME INC | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(5 years from now) | |
| US8691507 | EPIZYME INC | Inhibitors of human EZH2 and methods of use thereof |
Sep, 2031
(5 years from now) | |
| US9175331 | EPIZYME INC | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(5 years from now) | |
| US8895245 | EPIZYME INC | Inhibitors of human EZH2 and methods of use thereof |
Sep, 2031
(5 years from now) | |
| US9949999 | EPIZYME INC | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(5 years from now) | |
| US10369155 | EPIZYME INC | Method for treating cancer |
Oct, 2035
(9 years from now) | |
| US10420775 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US12168014 | EPIZYME INC | Method for treating cancer |
May, 2038
(12 years from now) | |
| US12162865 | EPIZYME INC | Methods of treating cancer |
Jun, 2034
(8 years from now) | |
| US12168016 | EPIZYME INC | Aryl-OR heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US10155002 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US9688665 | EPIZYME INC | Methods of treating cancer |
Aug, 2034
(8 years from now) | |
| US9855275 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US10245269 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(7 years from now) | |
| US12161645 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US11491163 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(7 years from now) | |
| US10786511 | EPIZYME INC | Method for treating cancer |
Dec, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-835) | Jun 18, 2023 |
| New Indication(I-836) | Jun 18, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jan 23, 2025 |
| Orphan Drug Exclusivity(ODE-299) | Jan 23, 2027 |
| Orphan Drug Exclusivity(ODE-314) | Jun 18, 2027 |
Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient
NCE-1 date: 24 January, 2024
Market Authorisation Date: 23 January, 2020
Dosage: TABLET
More Information on Dosage
TAZVERIK family patents
3. Votrient patent
expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8114885 | NOVARTIS | Chemical compounds |
Dec, 2021
(4 years ago) | |
| US7262203 | NOVARTIS | Pyrimidineamines as angiogenesis modulators |
Dec, 2021
(4 years ago) | |
| US7105530 | NOVARTIS | Pyrimidineamines as angiogenesis modulators |
Oct, 2023
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 19, 2014 |
| New Indication(I-649) | Apr 26, 2015 |
| Orphan Drug Exclusivity(ODE) | Apr 26, 2019 |
| Orphan Drug Exclusivity(ODE-23) | Apr 26, 2019 |
Drugs and Companies using PAZOPANIB HYDROCHLORIDE ingredient
NCE-1 date: 19 October, 2013
Market Authorisation Date: 19 October, 2009
Dosage: TABLET
More Information on Dosage
VOTRIENT family patents
4. Yondelis patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8895557 | JANSSEN PRODS | Pharmaceutical formulations of ecteinascidin compounds |
Jan, 2028
(1 year, 11 months from now) | |
|
US8895557 (Pediatric) | JANSSEN PRODS | Pharmaceutical formulations of ecteinascidin compounds |
Jul, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 23, 2020 |
| M(M-232) | Jun 29, 2021 |
| Orphan Drug Exclusivity(ODE) | Oct 23, 2022 |
| Orphan Drug Exclusivity(ODE-100) | Oct 23, 2022 |
| Pediatric Exclusivity(PED) | Apr 23, 2023 |
Drugs and Companies using TRABECTEDIN ingredient
NCE-1 date: 23 April, 2022
Market Authorisation Date: 23 October, 2015
Dosage: POWDER
How can I launch a generic of YONDELIS before it's drug patent expiration?
More Information on Dosage
YONDELIS family patents